Back to Screener

GRAIL, Inc. Common Stock (GRAL)

Price$49.47

Favorite Metrics

Price vs S&P 500 (26W)-35.58%
Price vs S&P 500 (4W)-2.97%
Market Capitalization$2.04B

All Metrics

Book Value / Share (Quarterly)$63.92
P/TBV (Annual)4.59x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)38.37%
Cash Flow / Share (Quarterly)$-7.44
Price vs S&P 500 (YTD)-44.47%
Gross Margin (TTM)48.46%
Net Profit Margin (TTM)-277.47%
EPS (TTM)$-11.18
10-Day Avg Trading Volume0.95M
EPS Excl Extra (TTM)$-11.18
EPS (Annual)$-11.11
ROI (Annual)-15.84%
Gross Margin (Annual)48.46%
Net Profit Margin (5Y Avg)-4344.87%
Cash / Share (Quarterly)$22.43
Revenue Growth QoQ (YoY)13.97%
ROA (Last FY)-13.97%
Revenue Growth TTM (YoY)17.18%
EBITD / Share (TTM)$-11.68
ROE (5Y Avg)-53.29%
Operating Margin (TTM)-381.98%
Cash Flow / Share (Annual)$-7.44
P/B Ratio0.79x
P/B Ratio (Quarterly)1.29x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)12.18x
ROA (TTM)-14.75%
EPS Incl Extra (Annual)$-11.11
Current Ratio (Annual)11.97x
Quick Ratio (Quarterly)11.78x
3-Month Avg Trading Volume1.15M
52-Week Price Return100.36%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$18.03
P/S Ratio (Annual)13.88x
Asset Turnover (Annual)0.05x
52-Week High$118.84
Operating Margin (5Y Avg)-4442.08%
EPS Excl Extra (Annual)$-11.11
CapEx CAGR (5Y)-22.88%
26-Week Price Return-31.60%
Quick Ratio (Annual)11.78x
13-Week Price Return-53.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.97x
Enterprise Value$1,792.671
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-363.18%
Cash / Share (Annual)$22.43
3-Month Return Std Dev134.11%
Gross Margin (5Y Avg)37.30%
Net Income / Employee (TTM)$-0
ROE (Last FY)-15.84%
EPS Basic Excl Extra (Annual)$-11.11
Receivables Turnover (TTM)7.62x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-11.18
Receivables Turnover (Annual)7.62x
ROI (TTM)-17.11%
P/S Ratio (TTM)13.88x
Pretax Margin (5Y Avg)-4431.73%
Revenue / Share (Annual)$4.00
Tangible BV / Share (Annual)$18.03
Price vs S&P 500 (52W)70.53%
Year-to-Date Return-41.83%
5-Day Price Return4.69%
EPS Normalized (Annual)$-11.11
ROA (5Y Avg)-48.30%
Net Profit Margin (Annual)-277.47%
Month-to-Date Return-3.66%
EBITD / Share (Annual)$-11.68
Operating Margin (Annual)-381.98%
ROI (5Y Avg)-53.29%
EPS Basic Excl Extra (TTM)$-11.18
P/TBV (Quarterly)4.59x
P/B Ratio (Annual)1.29x
Pretax Margin (TTM)-363.18%
Book Value / Share (Annual)$63.92
Price vs S&P 500 (13W)-53.68%
Beta1.93x
Revenue / Share (TTM)$3.61
ROE (TTM)-17.11%
52-Week Low$23.80

Analyst Recommendations

Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.08

Industry Peers — Health Services(20)

SymbolP/E Ratio (Annual)Revenue Growth TTM (YoY)Operating Margin (TTM)ROE (TTM)Price
GRALGRAIL, Inc. Common Stock
17.18%-381.98%-17.11%$49.47
NTRANatera, Inc. Common Stock
35.90%-13.44%-15.28%$196.11
LHLabcorp Holdings Inc.
25.08x7.25%9.92%10.28%$266.36
DGXQuest Diagnostics Inc.
21.24x11.78%14.10%13.88%$191.46
EXASExact Sciences Corp
17.69%-6.35%-8.51%$104.91
GHGuardant Health, Inc. Common Stock
32.88%-45.02%-246.60%$85.70
RDNTRadNet, Inc. Common Stock
1779.27x11.51%3.04%-1.88%$60.09
VCYTVeracyte, Inc.
40.04x16.01%11.17%5.33%$33.03
CDNACareDx, Inc.
18.34x13.79%-8.10%-6.47%$22.42
FTREFortrea Holdings Inc. Common Stock
1.00%-32.04%-152.17%$10.09
CSTLCastle Biosciences, Inc. Common Stock
47.31x3.66%-12.44%-5.27%$24.56

About

GRAIL Inc develops a blood-based test for multi-cancer early detection designed to identify various cancer types at earlier stages. The company provides testing services focused on enabling earlier diagnosis and intervention, operating as a single business segment dedicated to cancer detection technology.